SOURCE: CEO of ELENZA and Author of The EQUITY Series
As Chief Executive Officer of ELENZA, Inc., Mazzocchi was selected as one of this year's Top Innovators in the field of Life Sciences, and will present at the upcoming Venture Summit West Conference on February 13, 2013.
Mountain View, CA (PRWEB) February 05, 2013
Venture Summit West, presented by youngStartup Ventures, is the premier industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of early stage and emerging growth companies, university researchers, incubators and premier service providers. The event will take place on February 12-13th at the Computer History Museum in Silicon Valley, and will honor the 50 Top Innovators in Life Sciences, Cleantech and Software/IT.
As a Co-founder and/or Founding-CEO of nearly a dozen med-tech companies, Mazzocchi has now taken on a the challenging development effort to produce the first electronically-activated implantable lens for the multi-billion dollar ophthalmology device market. As recently described in The 2012 Best of Ophthalmology - Eye World News Magazine, ELENZA combines nanotechnology, artificial intelligence (neural networks-based memory), and advanced electronics to seamlessly autofocus an optic from far to near without movement.
"This is the most sophisticated computer chip and algorithm ever used in an implantable medical device," Mr. Mazzocchi said. "Within the first 300 seconds, this IOL is going to learn the specific pupil dynamics of that patient and customize its own internal algorithm. As the patient's needs change with time, the physician during a visit can reboot that algorithm and alter its program remotely and noninvasively. It's a patient-specific, adaptive, programmable IOL." ELENZA is currently making plans to initiate European Clinical Trials within the next 12 months to obtain CE Mark Approval by the end of 2014.
ELENZA, Inc. is a venture-funding company developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. These electro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life.
Rudy is best known as a medical device and biotechnology entrepreneur, inventor, and angel investor, with a history of starting new technology ventures throughout the U.S. and Europe. He’s been privileged to have the opportunity to see the newest innovations in healthcare and work with some of the most brilliant researchers, scientists and physicians in the industry.
Authoring more than 50 patents, he has helped pioneer new companies involved in cardiology, oncology, orthopedics, neurosurgery, ophthalmology and even embryonic stem-cell development. Through these efforts, he has become the recipient of many technology and business awards, including the Ernst & Young Entrepreneur of the Year Award in Healthcare and the National Businessman of the Year Award.
Combining these experiences and opportunities, with thousands of hours of travel and long evenings in hotel rooms, he found the initiative to start writing a collection of medical thrillers based on true events. His debut novel, EQUITY of EVIL, is currently ranked the #1 medical thriller on Amazon based on Customer Reviews.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10348116.htm